GrayBug, LLC, a company that focuses on the development of innovative injectable drug delivery systems to more effectively treat eye diseases, has announced the appointment of Michael O’Rourke as President & CEO, as well as Board Member.
“I am excited to take on this leadership role at this pivotal point in GrayBug’s development,” said Mr. O’Rourke. “GrayBug has developed a unique approach to offer superior treatment options to patients through proprietary sustained release drug platforms. I look forward to working with the team at GrayBug to advance our lead product for the treatment of neovascular eye diseases including wet age-related macular degeneration (wet-AMD).”
{iframe}http://globenewswire.com/news-release/2013/10/28/584153/10054677/en/GrayBug-LLC-Appoints-Michael-O-Rourke-as-President-CEO.html{/iframe}